JP2017514483A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017514483A5 JP2017514483A5 JP2016565257A JP2016565257A JP2017514483A5 JP 2017514483 A5 JP2017514483 A5 JP 2017514483A5 JP 2016565257 A JP2016565257 A JP 2016565257A JP 2016565257 A JP2016565257 A JP 2016565257A JP 2017514483 A5 JP2017514483 A5 JP 2017514483A5
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- genome
- albumin binding
- protein
- adenoviral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000701161 unidentified adenovirus Species 0.000 claims 20
- 102000009027 Albumins Human genes 0.000 claims 11
- 108010088751 Albumins Proteins 0.000 claims 11
- 101710094396 Hexon protein Proteins 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 210000000234 capsid Anatomy 0.000 claims 3
- 241000192016 Finegoldia magna Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 108700011201 Streptococcus IgG Fc-binding Proteins 0.000 claims 2
- 108020001507 fusion proteins Proteins 0.000 claims 2
- 102000037865 fusion proteins Human genes 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000000174 oncolytic effect Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 108700026758 Adenovirus hexon capsid Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 claims 1
- 108700020796 Oncogene Proteins 0.000 claims 1
- 108091034131 VA RNA Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 238000002255 vaccination Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14382162.7A EP2940128A1 (en) | 2014-04-30 | 2014-04-30 | Adenovirus comprising an albumin-binding moiety |
| EP14382162.7 | 2014-04-30 | ||
| PCT/EP2015/059593 WO2015166082A1 (en) | 2014-04-30 | 2015-04-30 | Adenovirus comprising an albumin-binding moiety |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017514483A JP2017514483A (ja) | 2017-06-08 |
| JP2017514483A5 true JP2017514483A5 (enExample) | 2018-06-14 |
| JP6639412B2 JP6639412B2 (ja) | 2020-02-05 |
Family
ID=50774820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016565257A Active JP6639412B2 (ja) | 2014-04-30 | 2015-04-30 | アルブミン結合部分を含んでなるアデノウイルス |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US10604549B2 (enExample) |
| EP (2) | EP2940128A1 (enExample) |
| JP (1) | JP6639412B2 (enExample) |
| KR (1) | KR102628234B1 (enExample) |
| CN (1) | CN106471125B (enExample) |
| AU (1) | AU2015254535B2 (enExample) |
| BR (1) | BR112016025297B1 (enExample) |
| CA (1) | CA2946650C (enExample) |
| IL (1) | IL248590B (enExample) |
| MX (1) | MX381286B (enExample) |
| RU (1) | RU2711371C2 (enExample) |
| WO (1) | WO2015166082A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201507393TA (en) | 2013-03-14 | 2015-10-29 | Salk Inst For Biological Studi | Oncolytic adenovirus compositions |
| EP2940128A1 (en) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
| ES2899913T3 (es) | 2014-09-24 | 2022-03-15 | Salk Inst For Biological Studi | Virus tumorales oncolíticos y métodos de uso |
| EP3390645B1 (en) | 2016-02-23 | 2022-09-14 | Salk Institute for Biological Studies | Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics |
| CA3013637A1 (en) | 2016-02-23 | 2017-08-31 | Salk Institute For Biological Studies | High throughput assay for measuring adenovirus replication kinetics |
| AU2017375633C1 (en) | 2016-12-12 | 2023-04-27 | Salk Institute For Biological Studies | Tumor-targeting synthetic adenoviruses and uses thereof |
| US11077199B2 (en) | 2017-08-09 | 2021-08-03 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
| WO2019074842A1 (en) * | 2017-10-09 | 2019-04-18 | Keith Black | ONCOLYTIC ANTICANCER IMMUNOTHERAPIES AND METHODS OF USE |
| AU2018372631B2 (en) | 2017-11-22 | 2025-06-05 | Mesoblast International Sarl | Cellular compositions and methods of treatment I |
| AU2019251356B2 (en) | 2018-04-09 | 2025-06-12 | Salk Institute For Biological Studies | Oncolytic adenovirus compositions with enhanced replication properties |
| US20210340279A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators |
| CN119955743A (zh) * | 2018-09-10 | 2025-05-09 | 上海锦斯生物技术有限公司 | 修饰的溶瘤病毒、其组合物和用途 |
| EP4219527A3 (en) | 2018-11-21 | 2023-08-09 | Mayo Foundation for Medical Education and Research | Adenoviruses and methods for using adenoviruses |
| EP3911671A1 (en) | 2019-04-29 | 2021-11-24 | Mayo Foundation for Medical Education and Research | Multivalent pd-l1 binding compounds for treating cancer |
| AU2020325825A1 (en) | 2019-08-05 | 2022-03-17 | Mesoblast International Sarl | Cellular compositions comprising viral vectors and methods of treatment |
| WO2021194183A1 (ko) * | 2020-03-25 | 2021-09-30 | ㈜큐리진 | 면역 회피성 항종양 아데노바이러스 |
| US20230293590A1 (en) | 2020-08-10 | 2023-09-21 | Mesoblast International Sárl | Cellular compositions and methods of treatment |
| WO2023109740A1 (zh) * | 2021-12-13 | 2023-06-22 | 康希诺生物股份公司 | 一种重组腺病毒载体疫苗吸入给药递送系统 |
| CN114159556B (zh) * | 2021-12-14 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 一种用于腺病毒载体疫苗免疫增强的蛋白质纳米递送载体 |
| WO2023120762A1 (ko) * | 2021-12-21 | 2023-06-29 | (주)큐리진 | 면역 회피성 항종양 아데노바이러스 |
| EP4458973A1 (en) * | 2021-12-21 | 2024-11-06 | Curigin Co.,Ltd. | Immune-cloaking antitumor adenovirus |
| EP4602078A2 (en) | 2022-10-11 | 2025-08-20 | Yale University | Compositions and methods of using cell-penetrating antibodies |
| CN115624524B (zh) * | 2022-10-25 | 2023-10-27 | 中国医科大学附属第一医院 | Peg化白蛋白修饰的溶瘤病毒静脉递送制剂的制备及其应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561343B2 (en) | 1981-10-19 | 1987-05-07 | Genentech Inc. | Human immune interferon by recombinant dna |
| DE3377363D1 (en) | 1982-03-31 | 1988-08-18 | Ajinomoto Kk | Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
| US5328988A (en) | 1987-10-26 | 1994-07-12 | Immunex Corporation | Interleukin-7 |
| US5457038A (en) | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
| KR970005042B1 (ko) | 1993-02-09 | 1997-04-11 | 한일합성섬유공업 주식회사 | 종양괴사인자-알파 뮤테인 |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| US5998205A (en) | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| US5641665A (en) | 1994-11-28 | 1997-06-24 | Vical Incorporated | Plasmids suitable for IL-2 expression |
| EP2180054A1 (en) * | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Methods and compositions for prolonging elimination half-times of bioactive compounds |
| EP1284294A4 (en) | 2000-05-26 | 2004-10-13 | Sumitomo Pharma | RECOMBINANT ADENOVIRUS WITH REDUCED SIDE EFFECTS (12/05/01) |
| GB0017720D0 (en) | 2000-07-19 | 2000-09-06 | Got A Gene Ab | Modified virus |
| WO2007050128A2 (en) * | 2005-05-31 | 2007-05-03 | Vectorlogics, Inc. | Shielded adenoviral vectors and methods of use |
| DK2012822T3 (da) | 2006-04-28 | 2010-05-25 | Univ Pennsylvania | Modificeret adenovirushexonprotein og anvendelser deraf |
| RU2557319C2 (ru) | 2007-07-16 | 2015-07-20 | Дженентек, Инк. | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ |
| CN101781636A (zh) | 2009-01-19 | 2010-07-21 | 中国人民解放军第二军医大学东方肝胆外科医院 | 一种含11型腺病毒纤毛蛋白基因的增殖型重组溶瘤腺病毒、其构建方法及其用途 |
| ES2385251B1 (es) | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| EP2558481B1 (en) | 2010-04-14 | 2017-12-20 | Mogam Biotechnology Research Institute | Hexon isolated from simian adenovirus serotype 19, hypervariable region thereof and chimeric adenovirus using the same |
| EP2940128A1 (en) | 2014-04-30 | 2015-11-04 | Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) | Adenovirus comprising an albumin-binding moiety |
-
2014
- 2014-04-30 EP EP14382162.7A patent/EP2940128A1/en not_active Withdrawn
-
2015
- 2015-04-30 RU RU2016146664A patent/RU2711371C2/ru active
- 2015-04-30 JP JP2016565257A patent/JP6639412B2/ja active Active
- 2015-04-30 EP EP15720960.2A patent/EP3137599A1/en active Pending
- 2015-04-30 KR KR1020167033433A patent/KR102628234B1/ko active Active
- 2015-04-30 US US15/307,408 patent/US10604549B2/en active Active
- 2015-04-30 MX MX2016014187A patent/MX381286B/es unknown
- 2015-04-30 AU AU2015254535A patent/AU2015254535B2/en active Active
- 2015-04-30 CA CA2946650A patent/CA2946650C/en active Active
- 2015-04-30 WO PCT/EP2015/059593 patent/WO2015166082A1/en not_active Ceased
- 2015-04-30 CN CN201580023575.8A patent/CN106471125B/zh active Active
- 2015-04-30 BR BR112016025297-7A patent/BR112016025297B1/pt active IP Right Grant
-
2016
- 2016-10-29 IL IL248590A patent/IL248590B/en active IP Right Grant
-
2020
- 2020-02-19 US US16/795,478 patent/US11578104B2/en active Active
-
2023
- 2023-01-10 US US18/152,562 patent/US20230331786A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017514483A5 (enExample) | ||
| RU2016146664A (ru) | Аденовирус, содержащий альбумин-связывающий участок | |
| JP5075839B2 (ja) | 癌の処置のための腫瘍崩壊性アデノウイルス | |
| ES2167365T5 (es) | Vectores adenovirales de origen animal y utilizacion en terapia genica. | |
| Raty et al. | Gene therapy: the first approved gene-based medicines, molecular mechanisms and clinical indications | |
| ES2466415T3 (es) | Construcción de recombinante de adenovirus oncolítico que expresa específicamente el factor inmunomodulador GM-CSF en células tumorales y usos del mismo | |
| Yang et al. | Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy | |
| Kaplan | Adenovirus-based cancer gene therapy | |
| ES2871907T3 (es) | Portadores de vacuna de adenovirus de chimpancé | |
| JP2014516536A5 (enExample) | ||
| JP2015057052A5 (enExample) | ||
| Xiao et al. | Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo | |
| JP2022500013A (ja) | グリコーゲンシンターゼキナーゼ−３（ｇｓｋ３）のコード領域を含む複製能力ある組換えウイルス及び異常細胞を殺す方法 | |
| Yokoda et al. | Oncolytic virotherapy in upper gastrointestinal tract cancers | |
| NZ537631A (en) | Oncolytic virus replicating selectively in tumor cells | |
| Sutter et al. | Gene therapy for gastric cancer: is it promising? | |
| JP2021500880A5 (enExample) | ||
| Ulasov et al. | Oncolytic adenoviruses: a thorny path to glioma cure | |
| Lundstrom | Application of viruses for gene therapy and vaccine development | |
| Yao et al. | Current targeting strategies for adenovirus vectors in cancer gene therapy | |
| JP2004505633A (ja) | アデノウイルスｅ１ｂ−５５ｋ単一アミノ酸変異体および使用方法 | |
| JP2013531681A5 (enExample) | ||
| Davis et al. | Application of oncolytic viruses for cure of colorectal cancer | |
| Qi et al. | Anti-Tumor Effect of a Novel Oncolytic Virus Based on Chimpanzee Adenovirus Type 6 | |
| Curiel et al. | Applications of viruses for cancer therapy |